Related Experiment Videos
Everolimus.
1Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. Jens.hasskarl@uniklinik-freiburg.de.
Summary
Everolimus is an oral mTOR inhibitor approved for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma. It also treats tuberous sclerosis complex-associated conditions like angiomyolipoma, SEGA, and seizures.
Area of Science:
- Oncology
- Pharmacology
Background:
- The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and survival, and its dysregulation is common in various cancers.
- Everolimus targets this pathway, offering a therapeutic strategy for cancer treatment.
Purpose of the Study:
- To summarize the approved indications and clinical activity of everolimus (RAD001) in oncology.
- To highlight its role as an oral protein kinase inhibitor targeting the mTOR pathway.
Main Methods:
- Review of European Medicines Agency (EMA) and Food and Drug Administration (FDA) approvals for Everolimus (Afinitor®, Votubia®).
- Summary of clinical trial data supporting its efficacy in various cancer types and TSC-related conditions.
Main Results:
- EMA approval for hormone receptor-positive, HER2/neu-negative advanced breast cancer, pancreatic and GI/lung neuroendocrine tumors, and advanced renal cell carcinoma.
- FDA approval for similar oncologic indications, plus renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC), and TSC-related seizures.
Conclusions:
- Everolimus is an established therapy for multiple advanced cancers and TSC-related conditions.
- Ongoing trials continue to explore the role of mTOR inhibition in oncology.